Rapidly expanding biotechnology firms are typically characterized by breakthrough clinical pipelines in oncology, gene editing, metabolic disorders, or rare diseases. Companies featuring proprietary therapeutic platforms and successful late-stage clinical trial readouts routinely capture high market attention, though high growth is frequently accompanied by extreme volatility and clinical-stage risk.